XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Changes in Equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share-based payments
Other comprehensive income
Attributable to non-controlling interests
Beginning balance at Dec. 31, 2023 € 74,353 € 74,040 € 2,530 € 313 € (1,184) € 67,499 € 4,944 € (62) € 313
Other comprehensive income for the period 1,233 1,225       166   1,059 8
Net income for the period 2,263 [1] 2,246       2,246     17
Comprehensive income 3,496 [1] 3,471       2,412   1,059 25
Dividend paid out of earnings (4,704) (4,704)       (4,704)      
Payment of dividends to non-controlling interests (31) 0             (31)
Share repurchase program [2] (302) (302)     (302)        
Share-based payment plans:                  
Exercise of stock options 7 7 0 7          
Issuance of restricted shares and vesting of existing restricted shares 0 0 3 (3) 115 (115)      
Value of services obtained from employees 173 173         173    
Tax effects of share-based payments 4 4         4    
Other changes arising from issuance of restricted shares [3] 1 1       1      
Ending balance at Jun. 30, 2024 € 72,997 72,690 2,533 317 (1,371) 65,093 5,121 997 307
Share-based payment plans:                  
Dividend paid per share (in euros per share) € 3.76                
Other comprehensive income for the period € 1,199 1,185       (194)   1,379 14
Net income for the period 3,355 3,314       3,314     41
Comprehensive income 4,554 4,499       3,120   1,379 55
Payment of dividends to non-controlling interests (13)               (13)
Share repurchase program [2] 0 0     0        
Reduction in share capital 0 0 (12) (492) 530 (26)      
Exercise of stock options 26 26 1 25          
Issuance of restricted shares and vesting of existing restricted shares 0   0 0 1 (1)      
Employee share ownership plan 154 154 4 150          
Value of services obtained from employees 132 132         132    
Tax effects of share-based payments 7 7         7    
Change in non-controlling interests without loss of control 0 (1)       (1)     1
Ending balance at Dec. 31, 2024 77,857 77,507 2,526 0 (840) 68,185 5,260 2,376 350
Other comprehensive income for the period (4,774) (4,736)       243   (4,979) (38)
Net income for the period 5,837 5,812       5,812     25
Comprehensive income 1,063 1,076       6,055   (4,979) (13)
Dividend paid out of earnings (4,772) (4,772)       (4,772)      
Payment of dividends to non-controlling interests (32) 0             (32)
Share repurchase program [2] (3,988) (3,988)     (3,988)        
Reduction in share capital 0   (74)   3,868 (3,794)      
Share-based payment plans:                  
Exercise of stock options 15 15 1 14          
Issuance of restricted shares and vesting of existing restricted shares [2] 0 0 3 (3) 0 0      
Value of services obtained from employees 177 177         177    
Tax effects of share-based payments (7) (7)         (7)    
Other changes arising from issuance of restricted shares [4] 15 15       15      
Other movements (b) [5] (34) 0       0     (34)
Ending balance at Jun. 30, 2025 € 70,279 € 70,008 € 2,456 € 11 € (975) € 65,689 € 5,430 € (2,603) € 271
Share-based payment plans:                  
Dividend paid per share (in euros per share) € 3.92                
[1] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2] See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).
[3] For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.
[4] For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.
[5]
(e)This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).